|
1
|
Marusyk A and Polyak K: Tumor
heterogeneity: causes and consequences. Biochim Biophys Acta.
1805:105–117. 2010.PubMed/NCBI
|
|
2
|
Fidler IJ: Tumor heterogeneity and the
biology of cancer invasion and metastasis. Cancer Res.
38:2651–2660. 1978.PubMed/NCBI
|
|
3
|
Nguyen DX, Bos PD and Massagué J:
Metastasis: from dissemination to organ-specific colonization. Nat
Rev Cancer. 9:274–284. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bansal N and Banerjee D: Tumor initiating
cells. Curr Pharm Biotechnol. 10:192–196. 2009. View Article : Google Scholar
|
|
5
|
Mueller MT, Hermann PC and Heeschen C:
Cancer stem cells as new therapeutic target to prevent tumour
progression and metastasis. Front Biosci. 2:602–613. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maheswaran S and Haber DA: Circulating
tumor cells: a window into cancer biology and metastasis. Curr Opin
Genet Dev. 20:96–99. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goodell MA, Brose K, Paradis G, et al:
Isolation and functional properties of murine hematopoietic stem
cells that are replicating in vivo. J Exp Med. 183:1797–1806. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bunting KD, Zhou S, Lu T, et al: Enforced
P-glycoprotein pump function in murine bone marrow cells results in
expansion of side population stem cells in vitro and repopulating
cells in vivo. Blood. 96:902–909. 2000.PubMed/NCBI
|
|
9
|
Zhou S, Schuetz JD, Bunting KD, et al: The
ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem
cells and is a molecular determinant of the side-population
phenotype. Nat Med. 7:1028–1034. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moserle L, Ghisi M, Amadori A, et al: Side
population and cancer stem cells: therapeutic implications. Cancer
Lett. 288:1–9. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu C and Alman BA: Side population cells
in human cancers. Cancer Lett. 268:1–9. 2008. View Article : Google Scholar
|
|
12
|
Liu FS: Mechanisms of chemotherapeutic
drug resistance in cancer therapy – a quick review. Taiwan J Obstet
Gynecol. 48:239–244. 2009.
|
|
13
|
Reya T, Morrison SJ, Clarke MF, et al:
Stem cells, cancer, and cancer stem cells. Nature. 414:105–111.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu C, Wei Q, Utomo V, et al: Side
population cells isolated from mesenchymal neoplasms have tumor
initiating potential. Cancer Res. 67:8216–8222. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Komuro H, Saihara R, Shinya M, et al:
Identification of side population cells (stem-like cell population)
in pediatric solid tumor cell lines. J Pediatr Surg. 42:2040–2045.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Murase M, Kano M, Tsukahara T, et al: Side
population cells have the characteristics of cancer stem-like
cells/cancer-initiating cells in bone sarcomas. Br J Cancer.
101:1425–1432. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang M, Zhang R, Yan M, et al: Detection
and characterization of side population in Ewing’s sarcoma SK-ES-1
cells in vitro. Biochem Biophys Res Commun. 391:1062–1066.
2010.PubMed/NCBI
|
|
18
|
Rettig WJ, Garin-Chesa P, Healey JH, et
al: Identification of endosialin, a cell surface glycoprotein of
vascular endothelial cells in human cancer. Proc Natl Acad Sci USA.
89:10832–10836. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dolznig H, Schweifer N, Puri C, et al:
Characterization of cancer stroma markers: in silico analysis of an
mRNA expression database for fibroblast activation protein and
endosialin. Cancer Immun. 5:102005.PubMed/NCBI
|
|
20
|
Rouleau C, Curiel M, Weber W, et al:
Endosialin protein expression and therapeutic target potential in
human solid tumors: sarcoma versus carcinoma. Clin Cancer Res.
14:7223–7236. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bagley RG, Honma N, Weber W, et al:
Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor
neovascularization. Microvasc Res. 76:180–188. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bagley RG, Rouleau C, St Martin T, et al:
Human endothelial precursor cells express tumor endothelial marker
1/endosialin/CD248. Mol Cancer Ther. 7:2536–2546. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bagley RG, Weber W, Rouleau C, et al:
Human mesenchymal stem cells from bone marrow express tumor
endothelial and stromal markers. Int J Oncol. 34:619–627. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bagley RG: Endosialin: from vascular
target to biomarker for human sarcomas. Biomark Med. 3:589–604.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rouleau C, Smale R, Jones C, et al:
Characterizing models for personalized medicine: endosialin in
sarcoma from cultured cells to mice to humans. In: Proceedings of
the American Association for Cancer Research/National Cancer
Institute/European Organization for Research and Treatment of
Cancer; Nov 15–19; Boston, USA. 2009, View Article : Google Scholar
|
|
26
|
Cao QZ, Niu G and Tan HR: In vitro growth
inhibition of human colonic tumor cells by Verapamil. World J
Gastroenterol. 11:2255–2259. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schmidt WF, Huber KR, Ettinger RS, et al:
Antiproliferative effect of verapamil alone on brain tumor cells in
vitro. Cancer Res. 48:3617–3621. 1988.PubMed/NCBI
|
|
28
|
Siemann DW and Keng PC: Cell cycle
specific toxicity of the Hoechst 33342 stain in untreated or
irradiated murine tumor cells. Cancer Res. 46:3556–3559.
1986.PubMed/NCBI
|
|
29
|
Machaliński B, Wiszniewska B, Baśkiewicz
M, et al: In vivo and in vitro studies on the toxicity of Hoechst
33342 (Ho342). Implications for employing Ho342 for the isolation
of haematopoietic stem cells. Ann Transplant. 3:5–13.
1998.PubMed/NCBI
|
|
30
|
Hanyu A, Kojima K, Hatake K, et al:
Functional in vivo optical imaging of tumor angiogenesis, growth,
and metastasis prevented by administration of anti-human VEGF
antibody in xenograft model of human fibrosarcoma HT1080 cells.
Cancer Sci. 100:2085–2092. 2009. View Article : Google Scholar
|
|
31
|
Yu S, Qin D, Shangary S, et al: Potent and
orally active small-molecule inhibitors of the MDM2-p53
interaction. J Med Chem. 52:7970–7973. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liang WC, Wu X, Peale FV, et al:
Cross-species vascular endothelial growth factor (VEGF)-blocking
antibodies completely inhibit the growth of human tumor xenografts
and measure the contribution of stromal VEGF. J Biol Chem.
281:951–961. 2006. View Article : Google Scholar
|
|
33
|
Braczkowski R, Schally AV, Plonowski A, et
al: Inhibition of proliferation in human MNNG/HOS osteosarcoma and
SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by
antagonists of growth hormone-releasing hormone: effects on
insulin-like growth factor II. Cancer. 95:1735–1745. 2002.
View Article : Google Scholar
|
|
34
|
Vihinen P, Riikonen T, Laine A, et al:
Integrin alpha 2 beta 1 in tumorigenic human osteosarcoma cell
lines regulates cell adhesion, migration, and invasion by
interaction with type I collagen. Cell Growth Differ. 7:439–447.
1996.PubMed/NCBI
|
|
35
|
Tainsky MA, Shamanski FL, Blair D, et al:
Human recipient cell for oncogene transfection studies. Mol Cell
Biol. 7:1280–1284. 1987.PubMed/NCBI
|
|
36
|
Frese KK and Tuveson DA: Maximizing mouse
cancer models. Nat Rev Cancer. 7:645–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Heremans H, Billiau A, Cassiman JJ, et al:
In vitro cultivation of human tumor tissues. II Morphological and
virological characterization of three cell lines. Oncology.
35:246–252. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
McAllister RM, Gardner MB, Greene AE, et
al: Cultivation in vitro of cells derived from a human
osteosarcoma. Cancer. 27:397–402. 1971. View Article : Google Scholar : PubMed/NCBI
|
